Omeros Corp. suspended a phase II dose-escalation study of its phosphodiesterase 10 (PDE10) inhibitor, OMS824, in Huntington's disease (HD) over FDA concern about higher-than-expected blood levels of the drug in a concurrent rat study, sending shares in the Seattle company (NASDAQ:OMER) down 12.3 percent to close at $12.12 Tuesday.